Search for: "Astellas Pharma Inc." Results 21 - 40 of 53
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
14 Oct 2009, 7:00 am
Here is IP Think Tank’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet. [read post]
5 Aug 2009, 5:35 am
Here is IP Think Tank’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet. [read post]
8 Oct 2009, 6:05 am
Here is IP Think Tank’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet. [read post]
27 Mar 2009, 8:00 am
Here is IP Think Tank’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet. [read post]
3 Sep 2014, 4:01 pm
This is the question which the IPKat posed last Friday, on learning that Case C-661/13 Astellas Pharma Inc. v Polpharma SA Pharmaceutical Works, a reference to the Court of Justice of the European Union (CJEU) of some questions relating to the so-called Bolar exemption, which spares some sorts of use of someone else's patent for experimental purposes from being a patent infringement. [read post]
19 Aug 2015, 10:43 am by Sophia Avouris
Presented by Astellas Pharma, Inc., the event took place during the WGC-Bridgestone Invitational. [read post]
20 Jul 2011, 4:04 am by Marie Louise
Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet. [read post]
22 Oct 2021, 2:10 pm by Tom Lamb
As stated in our initial article about serious Padcev skin reactions last month, we are investigating cases of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in patients using Padcev as possible drug injury lawsuits to be filed against Astellas Pharma US, Inc., the manufacturer of Padcev. [read post]
29 Aug 2014, 7:30 am
Readers may still be looking forward to a ruling from the Court of Justice of the European Union (CJEU) in Case C-661/13 Astellas Pharma Inc. v Polpharma SA Pharmaceutical Works, which was excitedly publicised by this Kat here and here on account of its potential for clarifying the scope of Bolar exemptions from patent infringement in favour of experimental use. [read post]
11 Oct 2018, 1:24 pm by David Jensen
., in support of DISC2-10973, PI Jonathan Lin of UC San Diego, dealing with photoreceptor diseases (score 88 out of 100)Laura Brady, research manager, Fighting Blindness of Dublin, Ireland, also in support of DISC2-10973Avril Daly, CEO, Retina International, also in support of DISC2-10973.Philip Beachy, Ernest and Amelia Gallo professor, Stanford, in support of his application, DISC2-11105, dealing with bladder cancer (score 90 out of 100)Don Reed, vice president of public policy,… [read post]
7 Sep 2012, 1:38 pm
Daniels, 42, of North Naples, a pharmaceutical representative, and his employer, Astellas Pharma U.S. [read post]
12 Jul 2016, 7:22 am by Law Offices of Jeffrey S. Glassman
Both defendants in the case have since been purchased by other firms – OSI by Japanese company Astellas Pharma and Genetech by Swiss firm Hoffman-La Roche AG. [read post]
24 Jun 2014, 6:58 am by Duets Guest Blogger
However, I have never resorted to choosing random letters out of a hat…which is the only explanation I can come up with for why Astellas Pharma US, Inc. chose this name. [read post]
15 Jan 2014, 7:38 am
Pharmaceutical Works and Japanese company Astellas Pharma Inc; if you must know, the patent is for novel quinuclidine derivatives and pharmaceutical preparations. [read post]